ATE208206T1 - Immunologische verbesserung mit intermittierender interleukin-2 therapie - Google Patents

Immunologische verbesserung mit intermittierender interleukin-2 therapie

Info

Publication number
ATE208206T1
ATE208206T1 AT94920673T AT94920673T ATE208206T1 AT E208206 T1 ATE208206 T1 AT E208206T1 AT 94920673 T AT94920673 T AT 94920673T AT 94920673 T AT94920673 T AT 94920673T AT E208206 T1 ATE208206 T1 AT E208206T1
Authority
AT
Austria
Prior art keywords
therapy
period
intermittent
infusions
interleukin
Prior art date
Application number
AT94920673T
Other languages
English (en)
Inventor
H Clifford Lane
Joseph A Kovacs
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE208206T1 publication Critical patent/ATE208206T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT94920673T 1993-05-19 1994-05-19 Immunologische verbesserung mit intermittierender interleukin-2 therapie ATE208206T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/063,315 US5419900A (en) 1993-05-19 1993-05-19 Immunologic enhancement with intermittent interleukin-2 therapy
PCT/US1994/005397 WO1994026293A1 (en) 1993-05-19 1994-05-19 Immunologic enhancement with intermittent interleukin-2 therapy

Publications (1)

Publication Number Publication Date
ATE208206T1 true ATE208206T1 (de) 2001-11-15

Family

ID=22048393

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94920673T ATE208206T1 (de) 1993-05-19 1994-05-19 Immunologische verbesserung mit intermittierender interleukin-2 therapie

Country Status (11)

Country Link
US (3) US5419900A (de)
EP (1) EP0702560B1 (de)
JP (1) JP4275193B2 (de)
AT (1) ATE208206T1 (de)
AU (1) AU691504B2 (de)
CA (1) CA2163219A1 (de)
DE (1) DE69428992T2 (de)
DK (1) DK0702560T3 (de)
ES (1) ES2167370T3 (de)
PT (1) PT702560E (de)
WO (1) WO1994026293A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5696079A (en) * 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
RU2117472C1 (ru) * 1995-08-22 1998-08-20 Андрей Юрьевич Егоров Противоопухолевое средство местно-резорбтивного действия на основе интерлейкина-2 человека
JP2002515730A (ja) * 1995-10-16 2002-05-28 カイロン コーポレイション 遺伝子発現を変調する因子のスクリーニング方法
KR100220645B1 (ko) * 1997-07-04 1999-09-15 구광시 벤젠유도체의 제조방법
US6498006B2 (en) * 1997-11-24 2002-12-24 Johnson T. Wong Methods for treatment of HIV and other infections using A T cell or viral activator and anti-retroviral combination therapy
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
JP4776075B2 (ja) 1998-12-31 2011-09-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改変ｈｉｖｅｎｖポリペプチド
AU2487300A (en) * 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US6921530B1 (en) * 1999-09-24 2005-07-26 Cornell Research Foundation, Inc. Low dose IL-2 for potentiation of immunity
AU2001287820A1 (en) * 2000-09-08 2002-03-22 Aventis Pasteur Use of lipopeptides for immunotherapy of hiv-positive subjects
FR2813793B1 (fr) * 2000-09-08 2003-01-24 Aventis Pasteur Utilisation de lipopeptides pour l'immunotherapie des sujets vih+
US6579521B2 (en) * 2000-10-20 2003-06-17 Chiron Corporation Methods of therapy for HIV infection
US20060159657A1 (en) * 2001-06-14 2006-07-20 Macromed, Incorporated Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
US20030003074A1 (en) * 2001-06-14 2003-01-02 Macromed, Inc. Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
EP2280074A3 (de) * 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen
EP1411770A4 (de) * 2001-07-05 2006-05-10 Chiron Corp Polynukleotide, die für antigene hiv-polypeptide des c-typs codieren, polypeptide und ihre verwendung
WO2003015697A2 (en) * 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
RU2201762C1 (ru) * 2001-10-09 2003-04-10 Свадовский Александр Игоревич Способ лечения внутримозговой опухоли головного мозга
JP5015601B2 (ja) 2003-10-21 2012-08-29 セダーズ−シナイ メディカル センター 中枢神経系の癌を含む癌の処置のための系および方法
US20070098685A1 (en) * 2005-01-19 2007-05-03 Brand Stephen J Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
CA2700436C (en) 2006-09-28 2017-04-18 John S. Yu Cancer vaccines and vaccination methods
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
EP2427485B1 (de) 2009-05-07 2016-12-07 ImmunoCellular Therapeutics, Ltd. Cd133-epitope
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
WO2013169691A1 (en) 2012-05-07 2013-11-14 Trustees Of Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
ES2662333T3 (es) 2013-02-14 2018-04-06 Immunocellular Therapeutics Ltd. Vacunas contra el cáncer y métodos de vacunación
WO2016057651A1 (en) 2014-10-09 2016-04-14 Dana-Farber Cancer Institute, Inc. Multiple-variable il-2 dose regimen for treating immune disorders
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
WO2021146436A2 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Biased il2 muteins methods and compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
US4863730A (en) 1986-03-21 1989-09-05 Cenfold Holdings, S.A. Immunotherapy for AIDS patients
US4868157A (en) 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 2-amino-1,2-dideoxy-D-glucose derivatives as host resistance enhancers in AIDS-immunocompromised hosts and methods of use
US4866157A (en) * 1987-11-10 1989-09-12 Sugio Otani Thermosetting aromatic resin composition
DE3818054C2 (de) * 1988-05-27 1994-02-17 Biotest Pharma Gmbh Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
FR2653020B1 (fr) * 1989-10-17 1993-03-26 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies.
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
WO1991011719A1 (en) 1990-01-26 1991-08-08 Washington Research Foundation Immune reactivity to expressed activated oncogenes for diagnosis and treatment of malignancy
FR2660863B1 (fr) * 1990-04-17 1994-01-21 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
US5696079A (en) 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy

Also Published As

Publication number Publication date
CA2163219A1 (en) 1994-11-24
US6190656B1 (en) 2001-02-20
PT702560E (pt) 2002-04-29
JP4275193B2 (ja) 2009-06-10
US6548055B1 (en) 2003-04-15
AU691504B2 (en) 1998-05-21
US5419900A (en) 1995-05-30
DE69428992D1 (de) 2001-12-13
EP0702560A1 (de) 1996-03-27
WO1994026293A1 (en) 1994-11-24
DK0702560T3 (da) 2002-02-25
DE69428992T2 (de) 2002-08-14
AU7137794A (en) 1994-12-12
JPH09500362A (ja) 1997-01-14
EP0702560B1 (de) 2001-11-07
ES2167370T3 (es) 2002-05-16

Similar Documents

Publication Publication Date Title
ATE208206T1 (de) Immunologische verbesserung mit intermittierender interleukin-2 therapie
Teodorczyk-Injeyan et al. Impairment of T cell activation in burn patients: a possible mechanism of thermal injury-induced immunosuppression
DK0504177T3 (da) IL-11, et pattedyrcytokin
MY103212A (en) Zinc-protamine-alpha interferon complex
ATE272708T1 (de) Immunregulation über die cd28-route
IL69731A (en) Homogeneous human interleukin 2,its preparation and pharmaceutical compositions containing it
ES2032382T3 (es) Metodo para preparar un medicamento para la prevencion o tratamiento de la endometriosis.
EP0625991A4 (de) Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute.
DK0626177T3 (da) Ernæring til personer inficeret med humant immundefekt-virus
MX9203319A (es) Metodo para la preparacion de cristales de alfa-2 interferona.
DE3887031D1 (de) Verabreichungsform für einen Antagonisten von Gamma-Interferon zur Bekämpfung einer GHK-assoziierten Autoimmunerkrankung.
IT8521468A0 (it) Procedimento per ottenere interferon leucocitario alfa-2dell'uomo.
ES2110009T3 (es) Derivados de la estreptolisina o.
KR950702120A (ko) 골다공증 치료를 위한 포스포네이트의 용도(use of phosphonates for the treatment of osteoporosis)
FR2662942B1 (fr) Medicament immunostimulant a base de glycopeptidolipides polaires de mycobacterium chelonae.
GR3006999T3 (de)
IT1237435B (it) Farmaco attivo nel ripristino della plasticita' neuronale.
Lane et al. Immunologic enhancement with intermittent interleukin-2 therapy
Whiteside The natural killer (NK) cell and synergistic antitumor effects of interferon-gamma and interleukin-2
Zunich et al. Methionine-enkephalin as immunomodulator therapy in human immunodeficiency virus infections: Clinical and immunological effects
Palladino Jr et al. Immunopharmacology of tumor necrosis factors α and β
Lein Immune-based therapies
Fitzgerald et al. Splenic T-lymphocyte functions during early syphilitic infection are complex
BG102182A (bg) Използване на иприфлавон за намаляване броя на сd8+ клетки
Kurpisz et al. Blast transformation of lymphocytes induced by spermatozoa obtained from spermatocoele

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification